Literature DB >> 22300789

mGluR3 and not mGluR2 receptors mediate the efficacy of NAAG peptidase inhibitor in validated model of schizophrenia.

Rafal T Olszewski, Tomasz Bzdega, Joseph H Neale.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22300789     DOI： 10.1016/j.schres.2012.01.007

Source DB:  PubMed          Journal:  Schizophr Res        ISSN： 0920-9964            Impact factor:   4.939


× No keyword cloud information.
  18 in total

Review 1.  A role for N-acetylaspartylglutamate (NAAG) and mGluR3 in cognition.

Authors:  Joseph H Neale; Rafal Olszewski
Journal:  Neurobiol Learn Mem       Date:  2019-01-07       Impact factor: 2.877

2.  Neurochemical Metabolomics Reveals Disruption to Sphingolipid Metabolism Following Chronic Haloperidol Administration.

Authors:  Joseph L McClay; Sarah A Vunck; Angela M Batman; James J Crowley; Robert E Vann; Patrick M Beardsley; Edwin J van den Oord
Journal:  J Neuroimmune Pharmacol       Date:  2015-04-08       Impact factor: 4.147

3.  N-acetylaspartylglutamate Inhibits Heroin Self-Administration and Heroin-Seeking Behaviors Induced by Cue or Priming in Rats.

Authors:  Huaqiang Zhu; Miaojun Lai; Weisheng Chen; Disen Mei; Fuqiang Zhang; Huifeng Liu; Wenhua Zhou
Journal:  Neurosci Bull       Date:  2017-05-22       Impact factor: 5.203

4.  Inhibition of glutamate-carboxypeptidase-II in dorsolateral prefrontal cortex: potential therapeutic target for neuroinflammatory cognitive disorders.

Authors:  Shengtao Yang; Dibyadeep Datta; Alvaro Duque; Yury M Morozov; Jon Arellano; Barbara S Slusher; Min Wang; Amy F T Arnsten
Journal:  Mol Psychiatry       Date:  2022-06-22       Impact factor: 13.437

5.  NAAG peptidase inhibitors and deletion of NAAG peptidase gene enhance memory in novel object recognition test.

Authors:  Karolina J Janczura; Rafal T Olszewski; Tomasz Bzdega; Dean J Bacich; Warren D Heston; Joseph H Neale
Journal:  Eur J Pharmacol       Date:  2012-11-29       Impact factor: 4.432

6.  Immunohistological and electrophysiological evidence that N-acetylaspartylglutamate is a co-transmitter at the vertebrate neuromuscular junction.

Authors:  Kathryn K Walder; Steve B Ryan; Tomasz Bzdega; Rafal T Olszewski; Joseph H Neale; Clark A Lindgren
Journal:  Eur J Neurosci       Date:  2012-11-08       Impact factor: 3.386

7.  Effects of N-acetylaspartylglutamate (NAAG) peptidase inhibition on release of glutamate and dopamine in prefrontal cortex and nucleus accumbens in phencyclidine model of schizophrenia.

Authors:  Daiying Zuo; Tomasz Bzdega; Rafal T Olszewski; John R Moffett; Joseph H Neale
Journal:  J Biol Chem       Date:  2012-05-08       Impact factor: 5.157

8.  NAAG peptidase inhibition in the periaqueductal gray and rostral ventromedial medulla reduces flinching in the formalin model of inflammation.

Authors:  Toshihiko Yamada; Daiying Zuo; Tatsuo Yamamoto; Rafal T Olszewski; Tomasz Bzdega; John R Moffett; Joseph H Neale
Journal:  Mol Pain       Date:  2012-09-12       Impact factor: 3.395

9.  NAAG peptidase inhibitors block cognitive deficit induced by MK-801 and motor activation induced by d-amphetamine in animal models of schizophrenia.

Authors:  R T Olszewski; K J Janczura; S R Ball; J C Madore; K M Lavin; J C-M Lee; M J Lee; E K Der; T J Hark; P R Farago; C P Profaci; T Bzdega; J H Neale
Journal:  Transl Psychiatry       Date:  2012-07-31       Impact factor: 6.222

10.  Enhanced Brain Delivery of 2-(Phosphonomethyl)pentanedioic Acid Following Intranasal Administration of Its γ-Substituted Ester Prodrugs.

Authors:  Michael Nedelcovych; Ranjeet P Dash; Lukáš Tenora; Sarah C Zimmermann; Alexandra J Gadiano; Caroline Garrett; Jesse Alt; Kristen R Hollinger; Elie Pommier; Andrej Jančařík; Camilo Rojas; Ajit G Thomas; Ying Wu; Krystyna Wozniak; Pavel Majer; Barbara S Slusher; Rana Rais
Journal:  Mol Pharm       Date:  2017-08-31       Impact factor: 5.364
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.